PTC Announces Phase 2 ALS Failure, Sells Priority Review Voucher for $150M

PTC Therapeutics has been making moves in the lead-up to Thanksgiving. The company recently shared news of a Phase 2 trial for their potential ALS treatment. They’ve been quite busy!

Unfortunately, the trial did not yield the desired results. As a result, PTC Therapeutics has decided to sell its priority review voucher for an impressive $150 million. This decision comes after the disappointing outcome of the ALS trial.

It’s important to stay informed about these developments in the world of finance and securities. Stay tuned for more updates on PTC Therapeutics and other companies making waves in the industry.